| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
|
Purity: ≥98%
Daidzein is a naturally occuring isoflavone phytoestrogen isolated from Leguminosae, used as a component of foods and dietary supplements. In a dose-dependent manner, daizéin inhibits the production of NO as well as the expression of the iNOS protein and mRNA. Another crucial transcription factor for iNOS, signal transducer and activator of transcription 1 (STAT-1), is likewise inhibited by daizenein. Protein content, alkaline phosphatase activity, and DNA content are all significantly elevated in cells when daizeben (1 μM and 10 μM) is added; these increases are approximately 1.4-, 1.5-, and 2.0-fold, respectively.
| Targets |
PPAR-γ; PPAR-α
|
|---|---|
| ln Vitro |
Daidzein inhibits the expression of the iNOS protein and mRNA as well as the generation of NO in a dose-dependent manner. Additionally, daizenein prevents the activation of another crucial transcription factor for iNOS, signal transducer and activator of transcription 1 (STAT-1). (Source: ) Daidzein (1 μM and 10 μM) significantly increases the amount of DNA, protein, and alkaline phosphatase activity in cells; these increases are approximately 1.4-, 1.5-, and 2.0-fold, respectively.[2] Daidzein (2-50 mM) increases the viability of osteoblasts by about 1.4-fold. The alkaline phosphatase activity and osteocalcin synthesis of osteoblasts are increased by approximately 1.4 and 2.0 times, respectively, by daifzein (2-100 mM). Osteoblast differentiation is stimulated by daizenein at different stages (from osteoprogenitors to terminally differentiated osteoblasts).[3] Calcium contents, deoxyribonucleic acid (DNA), and alkaline phosphatase activity are all markedly increased in bone tissues by daidzein (1 μM and 10 μM). Cycloheximide (1 μM) totally inhibits the rise in calcium content and alkaline phosphatase activity in bone tissues caused by dainzocine.[4]
|
| ln Vivo |
Daidzein causes body weight to decrease, a phenomenon that could be explained by female rats consuming less feed. In female rats, daidzein causes modest but non-significant reductions in the size of the mammary glands, uterine and ovarian weights.[5]
|
| Enzyme Assay |
Daidzein, a natural isoflavonoid found in Leguminosae, has received increasing attention because of its possible role in the prevention of osteoporosis. In the present investigation, primary osteoblastic cells isolated from newborn Wistar rats were used to investigate the effect of this isoflavonoid on osteoblasts. Daidzein (2-50 microM) increased the viability (P<0.05) of osteoblasts by about 1.4-fold. In addition, daidzein (2-100 microM) increased the alkaline phosphatase activity and osteocalcin synthesis (P<0.05) of osteoblasts by about 1.4- and 2.0-fold, respectively. Alkaline phosphatase and osteocalcin are phenotypic markers for early-stage differentiated osteoblasts and terminally differentiated osteoblasts, respectively. Our results indicated that daidzein stimulated osteoblast differentiation at various stages (from osteoprogenitors to terminally differentiated osteoblasts). We also investigated the effect of daidzein on bone morphogenetic protein (BMP) production in osteoblasts that display the mature osteoblast phenotype. The results indicated that BMP2 synthesis was elevated significantly in response to daidzein (the mRNA increased 5.0-fold, and the protein increased 7.0-fold), suggesting that some of the effects of daidzein on the cell may be mediated by the increased production of BMPs by the osteoblasts. In conclusion, daidzein has a direct stimulatory effect on bone formation in cultured osteoblastic cells in vitro, which may be mediated by increased production of BMPs in osteoblasts [1].
|
| Cell Assay |
Placing HEK293T cells on 24-well plates, they are grown to 70–80% confluence at a cell density of roughly 2.5×104 cells/well. The cells are then transfected using an X-treme GENE HP DNA Transfection Reagent with a plasmid expressing PPAR-α or PPAR-γ expression, and a plasmid containing the luciferase gene under the control of three tandem PPAR response elements (PPRE × 3 TK-luciferase) cyclically. The transfection efficiency is monitored by co-transfecting Renilla luciferase control vectors. Cells are incubated in DMSO-containing medium or different concentrations (6.25, 12.5, 25 μM) of Daidzein for an additional 24 hours following transfection. The luciferase activity of lysed cells is quantified and expressed as fold induction, which is standardized to the activity of the plasmid that controls renilla luciferase[1].
|
| Animal Protocol |
Mice: Male C57 (C57 bl/6) and Apoe KO (C57 background) mice aged 10 to 11 weeks are used for the experiments. Mice are given Moxifloxacin (100 mg/kg) for 3 days in order to aid in long-term stroke recovery. In an animal model of stroke, prophylactic antibiotic treatment has been demonstrated to effectively reduce mortality by attenuating peripheral infection. To further prevent dehydration, hydrogel (Clear H2O) is given and saline is injected subcutaneously every day. Mice that receive poststroke care (medication, hydration, and hydrogels with soft diet) during the acute phase (less than one week) begin to regain body weight by day five and continue to heal from stroke. For vehicle or Daidzein treatment, animals are chosen at random. After confirming the reperfusion of blood flow, vehicle or Daidzein (10 mg/kg) is administered subcutaneously within 30 minutes. This is done daily for 7 days, and then every other day for up to 1 month.
|
| References |
| Molecular Formula |
C15H10O4
|
|
|---|---|---|
| Molecular Weight |
254.24
|
|
| Exact Mass |
254.06
|
|
| Elemental Analysis |
C, 70.86; H, 3.96; O, 25.17
|
|
| CAS # |
486-66-8
|
|
| Related CAS # |
Daidzein (Standard);486-66-8;Daidzein-d4;1219803-57-2;Daidzein-d6;291759-05-2
|
|
| Appearance |
Solid powder
|
|
| LogP |
2.78
|
|
| tPSA |
70.67
|
|
| SMILES |
C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3)O)O
|
|
| InChi Key |
ZQSIJRDFPHDXIC-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C15H10O4/c16-10-3-1-9(2-4-10)13-8-19-14-7-11(17)5-6-12(14)15(13)18/h1-8,16-17H
|
|
| Chemical Name |
7-hydroxy-3-(4-hydroxyphenyl)chromen-4-one
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.83 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.83 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: 20 mg/mL (78.67 mM) in 50% PEG300 50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9333 mL | 19.6665 mL | 39.3329 mL | |
| 5 mM | 0.7867 mL | 3.9333 mL | 7.8666 mL | |
| 10 mM | 0.3933 mL | 1.9666 mL | 3.9333 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00951912 | Completed | Dietary Supplement: Placebo Dietary Supplement: Daidzein |
Type 2 Diabetes Mellitus | Sun Yat-sen University | August 2009 | Not Applicable |
| NCT01556737 | Completed | Dietary Supplement: High daidzein supplement Dietary Supplement: High genistein supplement |
Postmenopause | Wageningen University | November 2011 | Not Applicable |
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
